

QUARTERLY SALES (\$ mill.) Full Mar.31 Jun. 30 Sep. 30 Dec. 31 Year 756.7 2722.6 626.8 693.7 645.4 680 1 827 5 788 0 753.8 3049 4 742 1 907 0 909 5 8104 3369 0 1015.8 1016.1 3780 850.9 897.2 1125 1125 950 950 4150 EARNINGS PER SHAREA Full Mar.31 Jun. 30 Sep. 30 Dec. 31 Year .21 1.12 .27 .30 33 .30 .31 .39 .38 .28 1.35 38 .48 **.57** .48 **.51** .41 .47 1.75 2.00 .45 QUARTERLY DIVIDENDS PAID Full Mar.31 Jun.30 Sep.30 Dec.31 NO CASH DIVIDENDS

endar

2015

2016

2017

2018

2019

Cal-

endar

2015

2016

2017

2018

2019

Cal-

endar

2015

2016

2017

2019

Monster Beverage stock declined a bit on news of a dispute with The Coca-Cola Company. The shares are down roughly 15% in value since our October report. Investors headed for the exits in early November, 2018, after The Coca-Cola Company announced plans to launch two Coke-branded energy drinks. A dispute with Monster arose after this announcement. Since 2015, the companies have had an allied agreement whereby Coca-Cola markets and distributes Monster's energy drinks and includes no Coca-Cola energy beverages in the portfolio. Thus, Monster views the debuts as a violation of the deal. The latest development is that the Coca-Cola launch has been delayed to spring of 2019. Until a decision is made, this legal matter will likely weigh in MNST shares.

The selloff seems unwarranted, in our view. First, Coca-Cola owns slightly under

The selloff seems unwarranted, in our view. First, Coca-Cola owns slightly under one-fifth of Monster Beverage. Being an equity owner gives that company a vested interest in its success. Also, although Coca-Cola plans to introduce these energy drinks, their reception in the market is unknown. To wit, Monster has prevailed over competition before and recently ce-

Monster's place in the energy drink market appears solid. Demand for the company's numerous energy drinks remains high, especially in certain channels, including convenience stores and gas stations. Furthermore, higher pricing and ongoing product innovation ought to facilitate almost 10% sales growth this year. Lastly, the company's distribution arrangement with The Coca-Cola Company has allowed it to enter international markets. It continues to capitalize on this growth opportunity with recent launches in Ecuador and Ukraine. Healthy revenue growth, share repurchases, and a lower tax rate are expected to facilitate strong bottom-line results in 2019 and over the 3-to 5-year horizon.

Long-term investors should consider these neutrally ranked shares. The recent decline in the equity's valuation offers patient accounts a solid buying opportunity. This stock possesses above-average recovery potential over the 2021-2023 pull.

Nira Maharaj

January 18, 2019

(A) Fully diluted earnings. Excludes non recurring gains and (losses): '15, (\$0.53); '17, \$0.07. May not sum due to rounding. Next earnings report due early February.

**BEING PAID** 

(B) In millions, adjusted for stock splits.
(C) Includes intangibles. In '17: \$2365.7 million, \$3.79 share.

 Company's Financial Strength
 A+

 Stock's Price Stability
 50

 Price Growth Persistence
 90

 Earnings Predictability
 85